Rho’s new business segment aims to streamline regulatory approval

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/wavebreakmedia)
(Image: Getty/wavebreakmedia)

Related tags: regulatory approval, regulatory, New drug application, New drug, Investigational new drug, Developmental biology

Rho will expand its services with the addition of its Regulatory Strategy and Submissions business segment.

The full-service contract research organization’s (CRO) new segment will support the company’s goal of helping sponsors plan, develop, and submit marketing applications including new drug applications​ (NDAs), biological license applications (BLAs), and marketing authorization applications (MAAs).

Rob Woolson, an applied statistician, will lead the segment as chief strategist with his experience in US and ex-US regulatory submissions. Woolson told us, “The new segment will help streamline our approach to regulatory submissions by providing an integrated approach that brings regulatory, clinical, non-clinical, CMC, and statistical experts together.”

Kevin Barber will join the segment as the vice president along with 35 staff members.

This new segment will add an integrated approach allowing, regulatory, clinical, nonclinical, and statistical experts to work side-by-side. The team will work to support the approval of therapeutic products and help clients at all stages of development from pre-investigational new drug (IND) through post-approval.

“Rho has a long history of successfully helping sponsors develop and submit marketing applications, and this change will help support our continued growth an excellence in this area,”​ said Woolson. 

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us


View more